Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Bit Digital Inc (BTBT) Price & Performance

Amylx Pharmaceuticals IncTrade
Bit Digital IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Bit Digital Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.68 (market cap $2.64B), while Bit Digital Inc trades at $1.45 (market cap $471.05M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 5.6× Bit Digital Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.

AMLXBTBT
Market Cap
$2.64B$471.05M
Sector
HealthTechnology
52-Week High
$24.19$4.22
52-Week Low
$7.82$1.23
Enterprise Value
$2.39B$760.36M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

Bit Digital Inc

BTBT trades at $1.44, up 10.77% over 24 hours, but faces a bearish technical outlook with 14 sell signals against 2 buy signals. The company reported a net loss of $80.32 million in 2025, with a negative net income margin of -145.45%, though it maintains a gross profit margin of 55.57%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in subsequent quarters. The stock is closely watched by investors ahead of its Q2 2026 earnings release on August 13, 2026.

The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing inflows. Analyst consensus is bullish with a 100% buy rating from two firms and a $5.12 average price target, suggesting significant upside potential if the company can improve profitability. Key risks include execution challenges, competitive pressures, and reliance on external financing to sustain operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Bit Digital Inc

Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.

Read more on BTBT